Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
February 27, 2026

Quotient and Ipsen extend partnership for ultra-rare disease therapy

Quotient Sciences has extended its commercial partnership with Ipsen, focusing on the production of Sohonos (Palovarotene) for fibrodysplasia ossificans progressiva (FOP).

Quotient Sciences now has expanded capabilities for handling HPAPI and products with OELs at or below 1µg/m³. Credit: Akimov Igor / Shutterstock.com.